Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
32.82
-0.53 (-1.59%)
May 13, 2025, 4:00 PM - Market closed
Royalty Pharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Cash & Equivalents | 1,088 | 929.03 | 477.01 | 1,711 | 1,541 | 1,009 | Upgrade
|
| Short-Term Investments | 12.1 | 58.2 | 18.3 | 25.72 | 647.87 | 1,053 | Upgrade
|
| Cash & Short-Term Investments | 1,100 | 987.23 | 495.31 | 1,736 | 2,189 | 2,062 | Upgrade
|
| Cash Growth | 26.13% | 99.31% | -71.48% | -20.67% | 6.16% | 505.29% | Upgrade
|
| Accounts Receivable | 740.34 | 810.73 | 760.84 | 727.92 | 682.66 | 626.36 | Upgrade
|
| Receivables | 740.34 | 810.73 | 760.84 | 727.92 | 682.66 | 626.36 | Upgrade
|
| Other Current Assets | 3.08 | 4.19 | 18.04 | 90.52 | 6.63 | 8.6 | Upgrade
|
| Total Current Assets | 1,843 | 1,802 | 1,274 | 2,555 | 2,878 | 2,697 | Upgrade
|
| Long-Term Investments | 696.29 | 1,260 | 1,012 | 735.82 | 909.59 | 916.64 | Upgrade
|
| Other Intangible Assets | 5.32 | 5.32 | 1.78 | 14.5 | 5.67 | 28.67 | Upgrade
|
| Long-Term Accounts Receivable | 15,032 | 15,127 | 14,089 | 13,493 | 13,718 | 12,368 | Upgrade
|
| Other Long-Term Assets | 31.38 | 28.21 | 4.74 | 15.13 | 4.14 | 10 | Upgrade
|
| Total Assets | 17,608 | 18,223 | 16,382 | 16,813 | 17,516 | 16,020 | Upgrade
|
| Accounts Payable | 37.63 | 13.37 | 15.17 | 7.91 | 5.62 | 10.78 | Upgrade
|
| Accrued Expenses | 19.22 | 98.06 | 51.68 | 54.16 | 57.7 | 60.75 | Upgrade
|
| Current Portion of Long-Term Debt | 998.61 | 997.77 | - | 997.51 | - | - | Upgrade
|
| Other Current Liabilities | 127.4 | 144.41 | 94.53 | 107.2 | 107.93 | 236.37 | Upgrade
|
| Total Current Liabilities | 1,183 | 1,254 | 161.38 | 1,167 | 171.25 | 307.89 | Upgrade
|
| Long-Term Debt | 6,619 | 6,615 | 6,135 | 6,119 | 7,096 | 5,817 | Upgrade
|
| Other Long-Term Liabilities | 17.9 | 12.08 | 0.9 | 2.5 | - | - | Upgrade
|
| Total Liabilities | 7,820 | 7,880 | 6,298 | 7,288 | 7,267 | 6,124 | Upgrade
|
| Common Stock | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.1 | Upgrade
|
| Additional Paid-In Capital | 4,211 | 4,103 | 4,011 | 3,666 | 3,508 | 2,866 | Upgrade
|
| Retained Earnings | 2,481 | 2,846 | 2,518 | 1,965 | 2,255 | 1,921 | Upgrade
|
| Treasury Stock | -2.65 | -2.66 | -2.63 | -2.81 | -2.72 | -2.32 | Upgrade
|
| Comprehensive Income & Other | - | - | - | - | 16.49 | 34.4 | Upgrade
|
| Total Common Equity | 6,689 | 6,947 | 6,526 | 5,628 | 5,777 | 4,819 | Upgrade
|
| Minority Interest | 3,100 | 3,396 | 3,558 | 3,897 | 4,472 | 5,077 | Upgrade
|
| Shareholders' Equity | 9,789 | 10,342 | 10,084 | 9,525 | 10,249 | 9,896 | Upgrade
|
| Total Liabilities & Equity | 17,608 | 18,223 | 16,382 | 16,813 | 17,516 | 16,020 | Upgrade
|
| Total Debt | 7,617 | 7,612 | 6,135 | 7,116 | 7,096 | 5,817 | Upgrade
|
| Net Cash (Debt) | -6,518 | -6,625 | -5,640 | -5,380 | -4,907 | -3,755 | Upgrade
|
| Net Cash Per Share | -11.06 | -11.15 | -9.35 | -12.28 | -11.83 | -10.00 | Upgrade
|
| Filing Date Shares Outstanding | 421.37 | 433.32 | 446.69 | 443.17 | 432.96 | 388.13 | Upgrade
|
| Total Common Shares Outstanding | 425.59 | 445.99 | 446.69 | 443.17 | 432.96 | 388.14 | Upgrade
|
| Working Capital | 660.39 | 548.52 | 1,113 | 1,388 | 2,707 | 2,389 | Upgrade
|
| Book Value Per Share | 15.72 | 15.58 | 14.61 | 12.70 | 13.34 | 12.42 | Upgrade
|
| Tangible Book Value | 6,683 | 6,941 | 6,525 | 5,614 | 5,771 | 4,790 | Upgrade
|
| Tangible Book Value Per Share | 15.70 | 15.56 | 14.61 | 12.67 | 13.33 | 12.34 | Upgrade
|
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.